

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=172	N
Age	70.0 (11.1)	172
Sex: Men	105 (61.0%)	172
Tumor level:		172
0-6cm	61 (35.5%)	
7-12cm	86 (50.0%)	
13-15cm	25 (14.5%)	
Tumor stage:		172
0	14 (8.14%)	
I	41 (23.8%)	
II	59 (34.3%)	
III	58 (33.7%)	
Neoadjuvant treatment	92 (53.5%)	172
Type of resection:		172
Abdominoperineal resection	35 (20.3%)	
Anterior resection	117 (68.0%)	
Hartmann	20 (11.6%)	
Perforation	12 (6.98%)	172
Invasion circumferential margin	15 (8.72%)	172
Mesorecto quality:		171
Satisfactory	160 (93.6%)	
Partial	3 (1.75%)	
No-satisfactory	8 (4.68%)	
Recidive	2 (1.16%)	172
Months to recidive	28.0 [12.0;46.2]	172
Metastasis	26 (15.1%)	172
Months to Metastasis	21.5 [8.00;44.0]	172
Exitus	26 (15.1%)	172
Months to exitus	28.0 [12.0;46.2]	172


Table 2: According to Local Recurrence

	No event n= 170	Event n= 2	Crude HR	p-value	Multivariate HR
Age (10y)	7.02 (1.10)	5.90 (1.56)	0.51 [0.20;1.29]	0.155	0.00 [0;Inf]
Sex: Men	105 (61.8%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0;Inf]
Tumor level:					
0-6cm	60 (35.3%)	1 (50.0%)	0.38 [0.02;6.13]	0.497	0.00 [0;Inf]
7-12cm	86 (50.6%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0;Inf]
Tumor stage:					
0	14 (8.24%)	0 (0.00%)	1.00 [0.00;.]	1.000	2.90 [0;Inf]
II	57 (33.5%)	2 (100%)	1223323017 [0.00;.]	0.999	1383047255.10 [0;Inf]
III	58 (34.1%)	0 (0.00%)	1.00 [0.00;.]	1.000	0.00 [0;Inf]
Neoadjuvant treatment	91 (53.5%)	1 (50.0%)	0.94 [0.06;15.0]	0.966	0.00 [0;Inf]
Type of resection:					
Abdominoperineal resection	34 (20.0%)	1 (50.0%)	4.53 [0.28;73.1]	0.287	30696.19 [0;Inf]
Hartmann	20 (11.8%)	0 (0.00%)	0.00 [0.00;.]	0.999	3545312593181.59 [0;Inf]
Perforation	12 (7.06%)	0 (0.00%)	0.00 [0.00;.]	0.999	187706006628465.00 [0;Inf]
Invasion circumferential margin	15 (8.82%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0;Inf]
Mesorrecto quality:					
Partial	3 (1.78%)	0 (0.00%)	0.00 [0.00;.]	1.000	1626061074420117352801346663438 [0;Inf]
No-satisfactory	8 (4.73%)	0 (0.00%)	0.00 [0.00;.]	0.999	679227.58 [0;Inf]

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	172	127	93	65	35	13


Table 3: According to Metastasis

	No event n= 146	Event n= 26	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.95 (1.13)	7.31 (0.91)	1.38 [0.91;2.10]	0.132	1.61 [1.01; 2.58]	0.047	172
Sex: Men	92 (63.0%)	13 (50.0%)	0.60 [0.28;1.30]	0.200	0.57 [0.25; 1.31]	0.183	172
Tumor level:							172
0-6cm	49 (33.6%)	12 (46.2%)	0.66 [0.25;1.76]	0.405	0.49 [0.10; 2.55]	0.399	
7-12cm	78 (53.4%)	8 (30.8%)	0.32 [0.11;0.92]	0.035	0.27 [0.08; 0.91]	0.034	
Tumor stage:							172
0	13 (8.90%)	1 (3.85%)	0.58 [0.06;5.18]	0.624	1.01 [0.10;10.13]	0.991	
II	49 (33.6%)	10 (38.5%)	1.69 [0.53;5.38]	0.376	2.19 [0.62; 7.73]	0.224	
III	47 (32.2%)	11 (42.3%)	1.94 [0.62;6.08]	0.258	2.81 [0.80; 9.90]	0.109	
Neoadjuvant treatment	79 (54.1%)	13 (50.0%)	0.84 [0.39;1.81]	0.659	1.20 [0.41; 3.46]	0.742	172
Type of resection:							172
Abdominoperineal resection	28 (19.2%)	7 (26.9%)	1.72 [0.70;4.24]	0.235	2.12 [0.51; 8.90]	0.303	
Hartmann	16 (11.0%)	4 (15.4%)	1.56 [0.52;4.69]	0.432	1.42 [0.39; 5.21]	0.592	
Perforation	11 (7.53%)	1 (3.85%)	0.51 [0.07;3.79]	0.513	0.41 [0.05; 3.38]	0.404	172
Invasion circumferential margin	12 (8.22%)	3 (11.5%)	1.39 [0.42;4.62]	0.594	1.26 [0.32; 4.91]	0.743	172
Mesorecto quality:							171
Partial	2 (1.38%)	1 (3.85%)	2.76 [0.37;20.4]	0.320	0.51 [0.04; 6.61]	0.605	
No-satisfactory	7 (4.83%)	1 (3.85%)	0.68 [0.09;5.02]	0.704	0.23 [0.02; 2.43]	0.224	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	172	112	83	55	30	10

Table 4: According to Exitus


	No event n= 146	Event n= 26	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.90 (1.12)	7.61 (0.84)	2.05 [1.24;3.39]	0.005	2.04 [1.20; 3.44]	0.008	172
Sex: Men	90 (61.6%)	15 (57.7%)	0.87 [0.40;1.89]	0.718	0.94 [0.37; 2.35]	0.891	172
Tumor level:							172
0-6cm	49 (33.6%)	12 (46.2%)	2.32 [0.52;10.4]	0.270	0.84 [0.10; 6.88]	0.869	
7-12cm	74 (50.7%)	12 (46.2%)	1.82 [0.41;8.12]	0.435	1.58 [0.31; 8.07]	0.585	
Tumor stage:							172
0	14 (9.59%)	0 (0.00%)	0.00 [0.00;.]	0.997	0.00 [0.00; Inf]	0.997	
II	51 (34.9%)	8 (30.8%)	0.56 [0.22;1.46]	0.240	0.62 [0.22; 1.72]	0.355	
III	49 (33.6%)	9 (34.6%)	0.70 [0.28;1.76]	0.444	0.74 [0.26; 2.14]	0.576	
Neoadjuvant treatment	76 (52.1%)	16 (61.5%)	1.44 [0.65;3.17]	0.366	2.12 [0.84; 5.34]	0.112	172
Type of resection:							172
Abdominoperineal resection	26 (17.8%)	9 (34.6%)	2.51 [1.08;5.82]	0.032	3.80 [0.83;17.47]	0.086	
Hartmann	17 (11.6%)	3 (11.5%)	1.25 [0.36;4.35]	0.727	0.88 [0.22; 3.52]	0.853	
Perforation	10 (6.85%)	2 (7.69%)	1.04 [0.25;4.42]	0.953	0.48 [0.10; 2.45]	0.379	172
Invasion circumferential margin	12 (8.22%)	3 (11.5%)	1.38 [0.41;4.59]	0.601	1.43 [0.34; 6.05]	0.626	172
Mesorecto quality:							171
Partial	1 (0.69%)	2 (7.69%)	5.00 [1.17;21.3]	0.030	1.46 [0.21;10.19]	0.705	
No-satisfactory	7 (4.83%)	1 (3.85%)	0.78 [0.11;5.83]	0.813	0.30 [0.03; 3.16]	0.315	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	172	127	94	66	35	13

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	35	25	15	11	4	1
Ant	117	90	67	46	33	11
H	20	15	12	10	3	1

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	35	21	13	9	4	1
Ant	117	82	59	40	27	8
H	20	13	11	9	3	1

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	35	25	16	11	4	1
Ant	117	90	67	47	33	11
H	20	15	12	10	3	1

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	0 [0; 0]	12.62 [17.93; 6.96]	7.71 [12; 3.22]
24	0.8 [2.35; 0]	16 [21.98; 9.57]	14.78 [20.61; 8.53]
36	2.02 [4.82; 0]	21 [28.18; 13.1]	17.77 [24.21; 10.79]
48	2.02 [4.82; 0]	21 [28.18; 13.1]	22.26 [29.98; 13.69]
60	2.02 [4.82; 0]	21 [28.18; 13.1]	22.26 [29.98; 13.69]